Medication Options and Clinical Strategies for Treating Tardive Dyskinesia

Authors

Leslie L. Citrome, New York Medical CollegeFollow

DOI

10.4088/JCP.TV18059BR2C

Journal Title

The Journal of Clinical Psychiatry

First Page

TV18059BR2C

Document Type

Article

Publication Date

1-28-2020

Department

Psychiatry and Behavioral Sciences

Abstract

Valbenazine and deutetrabenazine are FDA-approved as treatment for tardive dyskinesia (TD). Both medications are vesicular monoamine transporter type 2 (VMAT2) inhibitors, and both are effective for reducing TD symptoms. Clinicians need to be aware of the adverse effects of valbenazine and deutetrabenazine, as well as other key differences between the two, in order to individualize treatment. Using the Abnormal Involuntary Movement Scale assists clinicians in assessing progress for each patient. Treating TD effectively with these new medications will reduce the burden of the condition for patients.

Recommended Citation

Citrome, L. L. (2020). Medication Options and Clinical Strategies for Treating Tardive Dyskinesia. The Journal of Clinical Psychiatry, 81 (2), TV18059BR2C. https://doi.org/10.4088/JCP.TV18059BR2C